<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0&amp;ff=20231228150809&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0&amp;ff=20231228150809&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Thu, 28 Dec 2023 20:08:10 +0000</lastbuilddate>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153186/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad837. doi: 10.1093/eurheartj/ehad837. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153186/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38153186</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad837>10.1093/eurheartj/ehad837</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153186</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Lale Tokgozoglu</dc:creator>
<dc:creator>Carl Orringer</dc:creator>
<dc:creator>Alberico L Catapano</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias</dc:title>
<dc:identifier>pmid:38153186</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad837</dc:identifier>
</item>
<item>
<title>Leveraging global coronary flow assessments to inform revascularization benefit in chronic coronary disease: time to test total heart flow</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad812. doi: 10.1093/eurheartj/ehad812. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38153129</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad812>10.1093/eurheartj/ehad812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153129</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leveraging global coronary flow assessments to inform revascularization benefit in chronic coronary disease: time to test total heart flow</dc:title>
<dc:identifier>pmid:38153129</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad812</dc:identifier>
</item>
<item>
<title>Metabolic Communication by SGLT2 Inhibition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSION: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065517. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell-engineered heart tissue.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152989</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065517>10.1161/CIRCULATIONAHA.123.065517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152989</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Anja M Billing</dc:creator>
<dc:creator>Young Chul Kim</dc:creator>
<dc:creator>Søren Gullaksen</dc:creator>
<dc:creator>Benedikt Schrage</dc:creator>
<dc:creator>Janice Raabe</dc:creator>
<dc:creator>Arvid Hutzfeldt</dc:creator>
<dc:creator>Fatih Demir</dc:creator>
<dc:creator>Elina Kovalenko</dc:creator>
<dc:creator>Moritz Lassé</dc:creator>
<dc:creator>Aurelien Dugourd</dc:creator>
<dc:creator>Robin Fallegger</dc:creator>
<dc:creator>Birgit Klampe</dc:creator>
<dc:creator>Johannes Jaegers</dc:creator>
<dc:creator>Qing Li</dc:creator>
<dc:creator>Olha Kravtsova</dc:creator>
<dc:creator>Maria Crespo-Masip</dc:creator>
<dc:creator>Amelia Palermo</dc:creator>
<dc:creator>Robert A Fenton</dc:creator>
<dc:creator>Elion Hoxha</dc:creator>
<dc:creator>Stefan Blankenberg</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:creator>Tobias B Huber</dc:creator>
<dc:creator>Esben Laugesen</dc:creator>
<dc:creator>Tanja Zeller</dc:creator>
<dc:creator>Maria Chrysopolou</dc:creator>
<dc:creator>Julio Saez-Rodriguez</dc:creator>
<dc:creator>Christina Magnussen</dc:creator>
<dc:creator>Thomas Eschenhagen</dc:creator>
<dc:creator>Alexander Staruschenko</dc:creator>
<dc:creator>Gary Siuzdak</dc:creator>
<dc:creator>Per L Poulsen</dc:creator>
<dc:creator>Clarissa Schwab</dc:creator>
<dc:creator>Friederike Cuello</dc:creator>
<dc:creator>Volker Vallon</dc:creator>
<dc:creator>Markus M Rinschen</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Metabolic Communication by SGLT2 Inhibition</dc:title>
<dc:identifier>pmid:38152989</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065517</dc:identifier>
</item>
<item>
<title>Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSIONS: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in 3 vascular compartments and, as such, could serve as a promising drug target for atheroprotection.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.064974. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Genetic and experimental studies support a causal involvement of IL-6 (interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Leveraging data from 522 681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6R (IL-6 receptor) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization, we assessed its effects on 3281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3301). Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease. For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 (C-X-C motif chemokine ligand 10) were associated with risk of coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease, with up to 67% of the effects of genetically downregulated IL-6 signaling on these end points mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher <i>CXCL10</i> expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in 3 vascular compartments and, as such, could serve as a promising drug target for atheroprotection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152968</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064974>10.1161/CIRCULATIONAHA.123.064974</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152968</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Savvina Prapiadou</dc:creator>
<dc:creator>Luka Živković</dc:creator>
<dc:creator>Barbara Thorand</dc:creator>
<dc:creator>Marc J George</dc:creator>
<dc:creator>Sander W van der Laan</dc:creator>
<dc:creator>Rainer Malik</dc:creator>
<dc:creator>Christian Herder</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:creator>Thor Ueland</dc:creator>
<dc:creator>Ola Kleveland</dc:creator>
<dc:creator>Pål Aukrust</dc:creator>
<dc:creator>Lars Gullestad</dc:creator>
<dc:creator>Jürgen Bernhagen</dc:creator>
<dc:creator>Gerard Pasterkamp</dc:creator>
<dc:creator>Annette Peters</dc:creator>
<dc:creator>Aroon D Hingorani</dc:creator>
<dc:creator>Jonathan Rosand</dc:creator>
<dc:creator>Martin Dichgans</dc:creator>
<dc:creator>Christopher D Anderson</dc:creator>
<dc:creator>Marios K Georgakis</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis</dc:title>
<dc:identifier>pmid:38152968</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064974</dc:identifier>
</item>
<item>
<title>INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSIONS: In summary, our findings shed light on the INO80-dependent remodeling of the chromatin landscape and transcriptional networks as a major mechanism underlying cardiac dysfunction in heart failure, and suggest INO80 as a potential preventative or interventional target.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065440. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Progressive remodeling of cardiac gene expression underlies decline in cardiac function, eventually leading to heart failure. However, the major determinants of transcriptional network switching from normal to failed hearts remain to be determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this study, we integrated human samples, genetic mouse models, and genomic approaches, including bulk RNA sequencing, single-cell RNA sequencing, chromatin immunoprecipitation followed by high-throughput sequencing, and assay for transposase-accessible chromatin with high-throughput sequencing, to identify the role of chromatin remodeling complex INO80 in heart homeostasis and dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The INO80 chromatin remodeling complex was abundantly expressed in mature cardiomyocytes, and its expression further increased in mouse and human heart failure. Cardiomyocyte-specific overexpression of <i>Ino80</i>, its core catalytic subunit, induced heart failure within 4 days. Combining RNA sequencing, high-throughput sequencing, and assay for transposase-accessible chromatin with high-throughput sequencing, we revealed INO80 overexpression-dependent reshaping of the nucleosomal landscape that remodeled a core set of transcription factors, most notably the MEF2 family, whose target genes were closely associated with cardiac function. Conditional cardiomyocyte-specific deletion of <i>Ino80</i> in an established mouse model of heart failure demonstrated remarkable preservation of cardiac function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In summary, our findings shed light on the INO80-dependent remodeling of the chromatin landscape and transcriptional networks as a major mechanism underlying cardiac dysfunction in heart failure, and suggest INO80 as a potential preventative or interventional target.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152931</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065440>10.1161/CIRCULATIONAHA.123.065440</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152931</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Zongna Ren</dc:creator>
<dc:creator>Wanqing Zhao</dc:creator>
<dc:creator>Dandan Li</dc:creator>
<dc:creator>Peng Yu</dc:creator>
<dc:creator>Lin Mao</dc:creator>
<dc:creator>Quanyi Zhao</dc:creator>
<dc:creator>Luyan Yao</dc:creator>
<dc:creator>Xuelin Zhang</dc:creator>
<dc:creator>Yandan Liu</dc:creator>
<dc:creator>Bingying Zhou</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure</dc:title>
<dc:identifier>pmid:38152931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065440</dc:identifier>
</item>
<item>
<title>Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 28. doi: 10.1161/CIRCRESAHA.123.322757. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diabetes is a major risk factor for atherosclerotic cardiovascular diseases with a 2-fold higher risk of cardiovascular events in people with diabetes compared with those without. Circulating monocytes are inflammatory effector cells involved in both type 2 diabetes (T2D) and atherogenesis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We investigated the relationship between circulating monocytes and cardiovascular risk progression in people with T2D, using phenotypic, transcriptomic, and metabolomic analyses. cardiovascular risk progression was estimated with coronary artery calcium score in a cohort of 672 people with T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Coronary artery calcium score was positively correlated with blood monocyte count and frequency of the classical monocyte subtype. Unsupervised k-means clustering based on monocyte subtype profiles revealed 3 main endotypes of people with T2D at varying risk of cardiovascular events. These observations were confirmed in a validation cohort of 279 T2D participants. The predictive association between monocyte count and major adverse cardiovascular events was validated through an independent prospective cohort of 757 patients with T2D. Integration of monocyte transcriptome analyses and plasma metabolomes showed a disruption of mitochondrial pathways (tricarboxylic acid cycle, oxidative phosphorylation pathway) that underlined a proatherogenic phenotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04353869.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152893</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322757>10.1161/CIRCRESAHA.123.322757</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152893</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jean-Baptiste Julla</dc:creator>
<dc:creator>Diane Girard</dc:creator>
<dc:creator>Marc Diedisheim</dc:creator>
<dc:creator>Pierre-Jean Saulnier</dc:creator>
<dc:creator>Bao Tran Vuong</dc:creator>
<dc:creator>Camille Blériot</dc:creator>
<dc:creator>Elena Carcarino</dc:creator>
<dc:creator>Joe De Keizer</dc:creator>
<dc:creator>Lucie Orliaguet</dc:creator>
<dc:creator>Ivan Nemazanyy</dc:creator>
<dc:creator>Charline Potier</dc:creator>
<dc:creator>Kennan Khider</dc:creator>
<dc:creator>Dorothy Chepngenoh Tonui</dc:creator>
<dc:creator>Tina Ejlalmanesh</dc:creator>
<dc:creator>Raphaelle Ballaire</dc:creator>
<dc:creator>Hendrick Mambu Mambueni</dc:creator>
<dc:creator>Stéphane Germain</dc:creator>
<dc:creator>Bénédicte Gaborit</dc:creator>
<dc:creator>Tiphaine Vidal-Trécan</dc:creator>
<dc:creator>Jean-Pierre Riveline</dc:creator>
<dc:creator>Henri-Jean Garchon</dc:creator>
<dc:creator>François Fenaille</dc:creator>
<dc:creator>Sophie Lemoine</dc:creator>
<dc:creator>Louis Potier</dc:creator>
<dc:creator>Florence Castelli</dc:creator>
<dc:creator>Aurélie Carlier</dc:creator>
<dc:creator>David Masson</dc:creator>
<dc:creator>Ronan Roussel</dc:creator>
<dc:creator>Claire Vandiedonck</dc:creator>
<dc:creator>Samy Hadjadj</dc:creator>
<dc:creator>Fawaz Alzaid</dc:creator>
<dc:creator>Jean-François Gautier</dc:creator>
<dc:creator>Nicolas Venteclef</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes</dc:title>
<dc:identifier>pmid:38152893</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322757</dc:identifier>
</item>
<item>
<title>Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc 1: A Nationwide Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSIONS: For patients with atrial fibrillation, all subgroups of CHA(2)DS(2)-VASc 1 were associated with lower incidence of arterial thromboembolism compared with age ≥75 years without other risk factors (ie, CHA(2)DS(2)-VASc 2) and a higher incidence compared with CHA(2)DS(2)-VASc 0. No statistically significant difference was identified between the subgroups of CHA(2)DS(2)-VASc 1. These findings support current recommendations that patients within this intermediate risk group could be...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Oral anticoagulation is suggested in patients with atrial fibrillation and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥1 (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65-74 years, and sex score). To assess granular differences within CHA<sub>2</sub>DS<sub>2</sub>-VASc 1, the incidence of arterial thromboembolism according to CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 subgroups was examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Danish National Patient Registry and the Danish Prescription Registry linked nationally to identify patients with atrial fibrillation from 2000 to 2021 without oral anticoagulation and categorized according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score: CHA<sub>2</sub>DS<sub>2</sub>-VASc 0 (male and female subjects); CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 (hypertension, heart failure, diabetes, vascular disease, and age 65-74 years); or CHA<sub>2</sub>DS<sub>2</sub>-VASc 2 (age ≥75 years without other risk factors). Female sex was not considered a risk factor in any risk group. The outcome was arterial thromboembolism (ischemic stroke, embolism of extremity, or transient cerebral ischemia). Study groups were compared using Cox regression analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 26 701 patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc 0 score; 22 915 with CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 (1483 patients with heart failure, 9066 with hypertension, 843 with diabetes, 770 with vascular disease, and 10 753 who were 65 to 74 years of age); and 14 525 patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc 2 (≥75 years of age without other risk factors). With a median of 1 year of observation time, the cumulative incidence of arterial thromboembolism was 0.6% (n=154 [95% CI, 0.6%-0.8%]), 1.4% (n=16 [95% CI, 0.8%-2.2%]), 1.9% (n=141 [95% CI, 1.6%-2.2%]), 1.7% (n=12 [95% CI, 0.9%-2.9%]), 2.0% (n=13 [95% CI, 1.1%-3.4%]), 2.3% (n=187 [95% CI, 2.0%-2.7%]), and 4.4% (n=533 [95% CI, 4.1%-4.8%]) for CHA<sub>2</sub>DS<sub>2</sub>-VASc 0, heart failure, hypertension, diabetes, vascular disease, age 65 to 74 years (CHA<sub>2</sub>DS<sub>2</sub>-VASc 1), and age ≥75 years (CHA<sub>2</sub>DS<sub>2</sub>-VASc 2), respectively. No statistically significant difference was identified among subgroups of CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 (<i>P</i>=0.15 for difference).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with atrial fibrillation, all subgroups of CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 were associated with lower incidence of arterial thromboembolism compared with age ≥75 years without other risk factors (ie, CHA<sub>2</sub>DS<sub>2</sub>-VASc 2) and a higher incidence compared with CHA<sub>2</sub>DS<sub>2</sub>-VASc 0. No statistically significant difference was identified between the subgroups of CHA<sub>2</sub>DS<sub>2</sub>-VASc 1. These findings support current recommendations that patients within this intermediate risk group could be identified with a similar risk of arterial thromboembolism.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152890</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066477>10.1161/CIRCULATIONAHA.123.066477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152890</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Lauge Østergaard</dc:creator>
<dc:creator>Jonas Bjerring Olesen</dc:creator>
<dc:creator>Jeppe Kofoed Petersen</dc:creator>
<dc:creator>Lukas Schak Nielsen</dc:creator>
<dc:creator>Søren Lund Kristensen</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Emil Fosbøl</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc 1: A Nationwide Study</dc:title>
<dc:identifier>pmid:38152890</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066477</dc:identifier>
</item>
<item>
<title>Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSIONS: These findings establish a novel DKK1-LRP5/6-GPCR pathway in inducing diabetic injuries and may resolve the long-standing conundrum as to why elevated blood DKK1 has deleterious effects. Thus, monitoring and therapeutic elimination of blood DKK1 may be a promising strategy to attenuate diabetic injuries.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad842. doi: 10.1093/eurheartj/ehad842. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Anti-hypertensive agents are one of the most frequently used drugs worldwide. However, no blood pressure-lowering strategy is superior to placebo with respect to survival in diabetic hypertensive patients. Previous findings show that Wnt co-receptors LDL receptor-related proteins 5 and 6 (LRP5/6) can directly bind to several G protein-coupled receptors (GPCRs). Because angiotensin II type 1 receptor (AT1R) is the most important GPCR in regulating hypertension, this study examines the possible mechanistic association between LRP5/6 and their binding protein Dickkopf-1 (DKK1) and activation of the AT1R and further hypothesizes that the LRP5/6-GPCR interaction may affect hypertension and potentiate cardiac impairment in the setting of diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The roles of serum DKK1 and DKK1-LRP5/6 signalling in diabetic injuries were investigated in human and diabetic mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Blood pressure up-regulation positively correlated with serum DKK1 elevations in humans. Notably, LRP5/6 physically and functionally interacted with AT1R. The loss of membrane LRP5/6 caused by injection of a recombinant DKK1 protein or conditional LRP5/6 deletions resulted in AT1R activation and hypertension, as well as β-arrestin1 activation and cardiac impairment, possibly because of multiple GPCR alterations. Importantly, unlike commonly used anti-hypertensive agents, administration of the anti-DKK1 neutralizing antibody effectively prevented diabetic cardiac impairment in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings establish a novel DKK1-LRP5/6-GPCR pathway in inducing diabetic injuries and may resolve the long-standing conundrum as to why elevated blood DKK1 has deleterious effects. Thus, monitoring and therapeutic elimination of blood DKK1 may be a promising strategy to attenuate diabetic injuries.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152853</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad842>10.1093/eurheartj/ehad842</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152853</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>En Ma</dc:creator>
<dc:creator>Da Wo</dc:creator>
<dc:creator>Jinxiao Chen</dc:creator>
<dc:creator>Hongwei Yan</dc:creator>
<dc:creator>Xiaohui Zhou</dc:creator>
<dc:creator>Jia He</dc:creator>
<dc:creator>Celiang Wu</dc:creator>
<dc:creator>Qing Wang</dc:creator>
<dc:creator>Changjing Zuo</dc:creator>
<dc:creator>Xiao Li</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Qingshu Meng</dc:creator>
<dc:creator>Liang Zheng</dc:creator>
<dc:creator>Luying Peng</dc:creator>
<dc:creator>Lidian Chen</dc:creator>
<dc:creator>Jun Peng</dc:creator>
<dc:creator>Dan-Ni Ren</dc:creator>
<dc:creator>Weidong Zhu</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice</dc:title>
<dc:identifier>pmid:38152853</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad842</dc:identifier>
</item>
<item>
<title>Fibrosing mediastinitis manifesting as refractory pleural effusion and severe pulmonary hypertension successfully treated by percutaneous pulmonary vein stenting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152845/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad862. doi: 10.1093/eurheartj/ehad862. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152845/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152845</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad862>10.1093/eurheartj/ehad862</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152845</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Ziling He</dc:creator>
<dc:creator>Danping Zhang</dc:creator>
<dc:creator>Xuefeng Wang</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fibrosing mediastinitis manifesting as refractory pleural effusion and severe pulmonary hypertension successfully treated by percutaneous pulmonary vein stenting</dc:title>
<dc:identifier>pmid:38152845</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad862</dc:identifier>
</item>
<item>
<title>Gastropericardial fistula complicated by severe multi-vessel coronary spasm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad860. doi: 10.1093/eurheartj/ehad860. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38152844</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad860>10.1093/eurheartj/ehad860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152844</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Qianfeng Xiao</dc:creator>
<dc:creator>Ying Xu</dc:creator>
<dc:creator>Si Wang</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gastropericardial fistula complicated by severe multi-vessel coronary spasm</dc:title>
<dc:identifier>pmid:38152844</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad860</dc:identifier>
</item>
<item>
<title>Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38150260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the STRONG-HF randomized clinical trial show that, among patients randomly assigned to high-intensity care, achieving higher doses of HF GDMT 2 weeks after discharge was feasible and safe in most patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 27. doi: 10.1001/jamacardio.2023.4553. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro-Brain Natriuretic Peptide Testing of Heart Failure Therapies (STRONG-HF) trial strived for rapid uptitration aiming to reach 100% optimal doses of guideline-directed medical therapy (GDMT) within 2 weeks after discharge from an acute heart failure (AHF) admission.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the association between degree of GDMT doses achieved in high-intensity care and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analysis of the STRONG-HF randomized clinical trial, conducted from May 2018 to September 2022. Included in the study were patients with AHF who were not treated with optimal doses of GDMT before and after discharge from an AHF admission. Data were analyzed from January to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: The mean percentage of the doses of 3 classes of HF medications (renin-angiotensin system inhibitors, β-blockers, and mineralocorticoid receptor antagonists) relative to their optimal doses was computed. Patients were classified into 3 dose categories: low (&lt;50%), medium (≥50% to &lt;90%), and high (≥90%). Dose and dose group were included as a time-dependent covariate in Cox regression models, which were used to test whether outcomes differed by dose.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME MEASURES: Post hoc secondary analyses of postdischarge 180-day HF readmission or death and 90-day change in quality of life.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 515 patients (mean [SD] age, 62.7 [13.4] years; 311 male [60.4%]) assigned high-intensity care were included in this analysis. At 2 weeks, 39 patients (7.6%) achieved low doses, 254 patients (49.3%) achieved medium doses, and 222 patients (43.1%) achieved high doses. Patients with lower blood pressure and more congestion were less likely to be uptitrated to optimal GDMT doses at week 2. As a continuous time-dependent covariate, an increase of 10% in the average percentage optimal dose was associated with a reduction in 180-day HF readmission or all-cause death (primary end point: adjusted hazard ratio [aHR], 0.89; 95% CI, 0.81-0.98; P = .01) and a decrease in 180-day all-cause mortality (aHR, 0.84; 95% CI, 0.73-0.95; P = .007). Quality of life at 90 days, measured by the EQ-5D visual analog scale, improved more in patients treated with higher doses of GDMT (mean difference, 0.10; 95% CI, -4.88 to 5.07 and 3.13; 95% CI, -1.98 to 8.24 points in the medium- and high-dose groups relative to the low-dose group, respectively; P = .07). Adverse events to day 90 occurred less frequently in participants with HIC who were prescribed higher GDMT doses at week 2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the STRONG-HF randomized clinical trial show that, among patients randomly assigned to high-intensity care, achieving higher doses of HF GDMT 2 weeks after discharge was feasible and safe in most patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03412201.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38150260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38150260</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4553>10.1001/jamacardio.2023.4553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38150260</guid>
<pubDate>Wed, 27 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Gad Cotter</dc:creator>
<dc:creator>Benjamin Deniau</dc:creator>
<dc:creator>Beth Davison</dc:creator>
<dc:creator>Christopher Edwards</dc:creator>
<dc:creator>Marianna Adamo</dc:creator>
<dc:creator>Mattia Arrigo</dc:creator>
<dc:creator>Marianela Barros</dc:creator>
<dc:creator>Jan Biegus</dc:creator>
<dc:creator>Jelena Celutkiene</dc:creator>
<dc:creator>Kamile Cerlinskaite-Bajore</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:creator>Alain Cohen-Solal</dc:creator>
<dc:creator>Albertino Damasceno</dc:creator>
<dc:creator>Rafael Diaz</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Etienne Gayat</dc:creator>
<dc:creator>Antoine Kimmoun</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Maria Novosadova</dc:creator>
<dc:creator>Peter S Pang</dc:creator>
<dc:creator>Matteo Pagnesi</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Hadiza Saidu</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Koji Takagi</dc:creator>
<dc:creator>Jozine M Ter Maaten</dc:creator>
<dc:creator>Daniela Tomasoni</dc:creator>
<dc:creator>Adriaan Voors</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:date>2023-12-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38150260</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4553</dc:identifier>
</item>
<item>
<title>STRONG-HF Evidence for Proactive, Patient-Centered Prescribing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38150243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 27. doi: 10.1001/jamacardio.2023.4565. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38150243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38150243</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4565>10.1001/jamacardio.2023.4565</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38150243</guid>
<pubDate>Wed, 27 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Jocelyn S Thompson</dc:creator>
<dc:creator>Josef Stehlik</dc:creator>
<dc:date>2023-12-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>STRONG-HF Evidence for Proactive, Patient-Centered Prescribing</dc:title>
<dc:identifier>pmid:38150243</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4565</dc:identifier>
</item>
<item>
<title>Variants at the Interleukin 1 Gene Locus and Pericarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38150231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: This study found an association between pericarditis and 2 independent sequence variants at the interleukin 1 gene locus. This finding has the potential to contribute to development of more targeted and personalized therapy of pericarditis with interleukin 1-blocking drugs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 27. doi: 10.1001/jamacardio.2023.4820. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Recurrent pericarditis is a treatment challenge and often a debilitating condition. Drugs inhibiting interleukin 1 cytokines are a promising new treatment option, but their use is based on scarce biological evidence and clinical trials of modest sizes, and the contributions of innate and adaptive immune processes to the pathophysiology are incompletely understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To use human genomics, transcriptomics, and proteomics to shed light on the pathogenesis of pericarditis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a meta-analysis of genome-wide association studies of pericarditis from 5 countries. Associations were examined between the pericarditis-associated variants and pericarditis subtypes (including recurrent pericarditis) and secondary phenotypes. To explore mechanisms, associations with messenger RNA expression (cis-eQTL), plasma protein levels (pQTL), and CpG methylation of DNA (ASM-QTL) were assessed. Data from Iceland (deCODE genetics, 1983-2020), Denmark (Copenhagen Hospital Biobank/Danish Blood Donor Study, 1977-2022), the UK (UK Biobank, 1953-2021), the US (Intermountain, 1996-2022), and Finland (FinnGen, 1970-2022) were included. Data were analyzed from September 2022 to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Genotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Pericarditis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this genome-wide association study of 4894 individuals with pericarditis (mean [SD] age at diagnosis, 51.4 [17.9] years, 2734 [67.6%] male, excluding the FinnGen cohort), associations were identified with 2 independent common intergenic variants at the interleukin 1 locus on chromosome 2q14. The lead variant was rs12992780 (T) (effect allele frequency [EAF], 31%-40%; odds ratio [OR], 0.83; 95% CI, 0.79-0.87; P = 6.67 × 10-16), downstream of IL1B and the secondary variant rs7575402 (A or T) (EAF, 45%-55%; adjusted OR, 0.89; 95% CI, 0.85-0.93; adjusted P = 9.6 × 10-8). The lead variant rs12992780 had a smaller odds ratio for recurrent pericarditis (0.76) than the acute form (0.86) (P for heterogeneity = .03) and rs7575402 was associated with CpG methylation overlapping binding sites of 4 transcription factors known to regulate interleukin 1 production: PU.1 (encoded by SPI1), STAT1, STAT3, and CCAAT/enhancer-binding protein β (encoded by CEBPB).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This study found an association between pericarditis and 2 independent sequence variants at the interleukin 1 gene locus. This finding has the potential to contribute to development of more targeted and personalized therapy of pericarditis with interleukin 1-blocking drugs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38150231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38150231</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4820>10.1001/jamacardio.2023.4820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38150231</guid>
<pubDate>Wed, 27 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Rosa B Thorolfsdottir</dc:creator>
<dc:creator>Andrea B Jonsdottir</dc:creator>
<dc:creator>Gardar Sveinbjornsson</dc:creator>
<dc:creator>Hildur M Aegisdottir</dc:creator>
<dc:creator>Asmundur Oddsson</dc:creator>
<dc:creator>Olafur A Stefansson</dc:creator>
<dc:creator>Gisli H Halldorsson</dc:creator>
<dc:creator>Saedis Saevarsdottir</dc:creator>
<dc:creator>Gudmar Thorleifsson</dc:creator>
<dc:creator>Lilja Stefansdottir</dc:creator>
<dc:creator>Ole B Pedersen</dc:creator>
<dc:creator>Erik Sørensen</dc:creator>
<dc:creator>Jonas Ghouse</dc:creator>
<dc:creator>Anna Axelsson Raja</dc:creator>
<dc:creator>Chaoqun Zheng</dc:creator>
<dc:creator>Elvira Silajdzija</dc:creator>
<dc:creator>Søren Albertsen Rand</dc:creator>
<dc:creator>Christian Erikstrup</dc:creator>
<dc:creator>Henrik Ullum</dc:creator>
<dc:creator>Christina Mikkelsen</dc:creator>
<dc:creator>Karina Banasik</dc:creator>
<dc:creator>Søren Brunak</dc:creator>
<dc:creator>Erna V Ivarsdottir</dc:creator>
<dc:creator>Asgeir Sigurdsson</dc:creator>
<dc:creator>Doruk Beyter</dc:creator>
<dc:creator>Arni Sturluson</dc:creator>
<dc:creator>Hafsteinn Einarsson</dc:creator>
<dc:creator>Vinicius Tragante</dc:creator>
<dc:creator>Hannes Helgason</dc:creator>
<dc:creator>Sigrun H Lund</dc:creator>
<dc:creator>Bjarni V Halldorsson</dc:creator>
<dc:creator>Brynja D Sigurpalsdottir</dc:creator>
<dc:creator>Isleifur Olafsson</dc:creator>
<dc:creator>David O Arnar</dc:creator>
<dc:creator>Gudmundur Thorgeirsson</dc:creator>
<dc:creator>Kirk U Knowlton</dc:creator>
<dc:creator>Lincoln D Nadauld</dc:creator>
<dc:creator>Solveig Gretarsdottir</dc:creator>
<dc:creator>Anna Helgadottir</dc:creator>
<dc:creator>Sisse R Ostrowski</dc:creator>
<dc:creator>Daniel F Gudbjartssson</dc:creator>
<dc:creator>Ingileif Jonsdottir</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Hilma Holm</dc:creator>
<dc:creator>Patrick Sulem</dc:creator>
<dc:creator>Kari Stefansson</dc:creator>
<dc:creator>Danish Blood Donor Study Genomic Consortium</dc:creator>
<dc:date>2023-12-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Variants at the Interleukin 1 Gene Locus and Pericarditis</dc:title>
<dc:identifier>pmid:38150231</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4820</dc:identifier>
</item>
<item>
<title>Lessons From Genetics About the Interleukin 1 Gene and Treatment of Recurrent Pericarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38150218/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 27. doi: 10.1001/jamacardio.2023.4831. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38150218/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38150218</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4831>10.1001/jamacardio.2023.4831</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38150218</guid>
<pubDate>Wed, 27 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Brittany Weber</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2023-12-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Lessons From Genetics About the Interleukin 1 Gene and Treatment of Recurrent Pericarditis</dc:title>
<dc:identifier>pmid:38150218</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4831</dc:identifier>
</item>
<item>
<title>Correction to: Fulminant myocarditis proven by early biopsy and outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38149435/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 27:ehad813. doi: 10.1093/eurheartj/ehad813. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38149435/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38149435</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad813>10.1093/eurheartj/ehad813</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38149435</guid>
<pubDate>Wed, 27 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Fulminant myocarditis proven by early biopsy and outcomes</dc:title>
<dc:identifier>pmid:38149435</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad813</dc:identifier>
</item>
<item>
<title>More blood for patients with myocardial infarction and anaemia?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38141126/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 23:ehad832. doi: 10.1093/eurheartj/ehad832. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38141126/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38141126</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad832>10.1093/eurheartj/ehad832</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38141126</guid>
<pubDate>Sat, 23 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2023-12-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>More blood for patients with myocardial infarction and anaemia?</dc:title>
<dc:identifier>pmid:38141126</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad832</dc:identifier>
</item>
<item>
<title>Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>Deciphering the cell-state transitions underlying immune adaptation across time is fundamental for advancing biology. Empirical in vivo genomic technologies that capture cellular dynamics are currently lacking. We present Zman-seq, a single-cell technology recording transcriptomic dynamics across time by introducing time stamps into circulating immune cells, tracking them in tissues for days. Applying Zman-seq resolved cell-state and molecular trajectories of the dysfunctional immune...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 13:S0092-8674(23)01317-X. doi: 10.1016/j.cell.2023.11.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Deciphering the cell-state transitions underlying immune adaptation across time is fundamental for advancing biology. Empirical in vivo genomic technologies that capture cellular dynamics are currently lacking. We present Zman-seq, a single-cell technology recording transcriptomic dynamics across time by introducing time stamps into circulating immune cells, tracking them in tissues for days. Applying Zman-seq resolved cell-state and molecular trajectories of the dysfunctional immune microenvironment in glioblastoma. Within 24 hours of tumor infiltration, cytotoxic natural killer cells transitioned to a dysfunctional program regulated by TGFB1 signaling. Infiltrating monocytes differentiated into immunosuppressive macrophages, characterized by the upregulation of suppressive myeloid checkpoints Trem2, Il18bp, and Arg1, over 36 to 48 hours. Treatment with an antagonistic anti-TREM2 antibody reshaped the tumor microenvironment by redirecting the monocyte trajectory toward pro-inflammatory macrophages. Zman-seq is a broadly applicable technology, enabling empirical measurements of differentiation trajectories, which can enhance the development of more efficacious immunotherapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38134933</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.032>10.1016/j.cell.2023.11.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134933</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Daniel Kirschenbaum</dc:creator>
<dc:creator>Ken Xie</dc:creator>
<dc:creator>Florian Ingelfinger</dc:creator>
<dc:creator>Yonatan Katzenelenbogen</dc:creator>
<dc:creator>Kathleen Abadie</dc:creator>
<dc:creator>Thomas Look</dc:creator>
<dc:creator>Fadi Sheban</dc:creator>
<dc:creator>Truong San Phan</dc:creator>
<dc:creator>Baoguo Li</dc:creator>
<dc:creator>Pascale Zwicky</dc:creator>
<dc:creator>Ido Yofe</dc:creator>
<dc:creator>Eyal David</dc:creator>
<dc:creator>Kfir Mazuz</dc:creator>
<dc:creator>Jinchao Hou</dc:creator>
<dc:creator>Yun Chen</dc:creator>
<dc:creator>Hila Shaim</dc:creator>
<dc:creator>Mayra Shanley</dc:creator>
<dc:creator>Soeren Becker</dc:creator>
<dc:creator>Jiawen Qian</dc:creator>
<dc:creator>Marco Colonna</dc:creator>
<dc:creator>Florent Ginhoux</dc:creator>
<dc:creator>Katayoun Rezvani</dc:creator>
<dc:creator>Fabian J Theis</dc:creator>
<dc:creator>Nir Yosef</dc:creator>
<dc:creator>Tobias Weiss</dc:creator>
<dc:creator>Assaf Weiner</dc:creator>
<dc:creator>Ido Amit</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma</dc:title>
<dc:identifier>pmid:38134933</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.032</dc:identifier>
</item>
<item>
<title>Sensory neurons promote immune homeostasis in the lung</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>Cytokines employ downstream Janus kinases (JAKs) to promote chronic inflammatory diseases. JAK1-dependent type 2 cytokines drive allergic inflammation, and patients with JAK1 gain-of-function (GoF) variants develop atopic dermatitis (AD) and asthma. To explore tissue-specific functions, we inserted a human JAK1 GoF variant (JAK1^(GoF)) into mice and observed the development of spontaneous AD-like skin disease but unexpected resistance to lung inflammation when JAK1^(GoF) expression was...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 13:S0092-8674(23)01313-2. doi: 10.1016/j.cell.2023.11.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cytokines employ downstream Janus kinases (JAKs) to promote chronic inflammatory diseases. JAK1-dependent type 2 cytokines drive allergic inflammation, and patients with JAK1 gain-of-function (GoF) variants develop atopic dermatitis (AD) and asthma. To explore tissue-specific functions, we inserted a human JAK1 GoF variant (JAK1<sup>GoF</sup>) into mice and observed the development of spontaneous AD-like skin disease but unexpected resistance to lung inflammation when JAK1<sup>GoF</sup> expression was restricted to the stroma. We identified a previously unrecognized role for JAK1 in vagal sensory neurons in suppressing airway inflammation. Additionally, expression of Calcb/CGRPβ was dependent on JAK1 in the vagus nerve, and CGRPβ suppressed group 2 innate lymphoid cell function and allergic airway inflammation. Our findings reveal evolutionarily conserved but distinct functions of JAK1 in sensory neurons across tissues. This biology raises the possibility that therapeutic JAK inhibitors may be further optimized for tissue-specific efficacy to enhance precision medicine in the future.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38134932</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.027>10.1016/j.cell.2023.11.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134932</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Masato Tamari</dc:creator>
<dc:creator>Kate L Del Bel</dc:creator>
<dc:creator>Aaron M Ver Heul</dc:creator>
<dc:creator>Lydia Zamidar</dc:creator>
<dc:creator>Keisuke Orimo</dc:creator>
<dc:creator>Masato Hoshi</dc:creator>
<dc:creator>Anna M Trier</dc:creator>
<dc:creator>Hiroshi Yano</dc:creator>
<dc:creator>Ting-Lin Yang</dc:creator>
<dc:creator>Catherine M Biggs</dc:creator>
<dc:creator>Kenichiro Motomura</dc:creator>
<dc:creator>Rintaro Shibuya</dc:creator>
<dc:creator>Chuyue D Yu</dc:creator>
<dc:creator>Zili Xie</dc:creator>
<dc:creator>Hisato Iriki</dc:creator>
<dc:creator>Zhen Wang</dc:creator>
<dc:creator>Kelsey Auyeung</dc:creator>
<dc:creator>Gargi Damle</dc:creator>
<dc:creator>Deniz Demircioglu</dc:creator>
<dc:creator>Jill K Gregory</dc:creator>
<dc:creator>Dan Hasson</dc:creator>
<dc:creator>Jinye Dai</dc:creator>
<dc:creator>Rui B Chang</dc:creator>
<dc:creator>Hideaki Morita</dc:creator>
<dc:creator>Kenji Matsumoto</dc:creator>
<dc:creator>Sanjay Jain</dc:creator>
<dc:creator>Steven Van Dyken</dc:creator>
<dc:creator>Joshua D Milner</dc:creator>
<dc:creator>Dusan Bogunovic</dc:creator>
<dc:creator>Hongzhen Hu</dc:creator>
<dc:creator>David Artis</dc:creator>
<dc:creator>Stuart E Turvey</dc:creator>
<dc:creator>Brian S Kim</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Sensory neurons promote immune homeostasis in the lung</dc:title>
<dc:identifier>pmid:38134932</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.027</dc:identifier>
</item>
<item>
<title>Automatic cell-type harmonization and integration across Human Cell Atlas datasets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134877/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>Harmonizing cell types across the single-cell community and assembling them into a common framework is central to building a standardized Human Cell Atlas. Here, we present CellHint, a predictive clustering tree-based tool to resolve cell-type differences in annotation resolution and technical biases across datasets. CellHint accurately quantifies cell-cell transcriptomic similarities and places cell types into a relationship graph that hierarchically defines shared and unique cell subtypes....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5876-5891.e20. doi: 10.1016/j.cell.2023.11.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Harmonizing cell types across the single-cell community and assembling them into a common framework is central to building a standardized Human Cell Atlas. Here, we present CellHint, a predictive clustering tree-based tool to resolve cell-type differences in annotation resolution and technical biases across datasets. CellHint accurately quantifies cell-cell transcriptomic similarities and places cell types into a relationship graph that hierarchically defines shared and unique cell subtypes. Application to multiple immune datasets recapitulates expert-curated annotations. CellHint also reveals underexplored relationships between healthy and diseased lung cell states in eight diseases. Furthermore, we present a workflow for fast cross-dataset integration guided by harmonized cell types and cell hierarchy, which uncovers underappreciated cell types in adult human hippocampus. Finally, we apply CellHint to 12 tissues from 38 datasets, providing a deeply curated cross-tissue database with ∼3.7 million cells and various machine learning models for automatic cell annotation across human tissues.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134877/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38134877</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.026>10.1016/j.cell.2023.11.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134877</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Chuan Xu</dc:creator>
<dc:creator>Martin Prete</dc:creator>
<dc:creator>Simone Webb</dc:creator>
<dc:creator>Laura Jardine</dc:creator>
<dc:creator>Benjamin J Stewart</dc:creator>
<dc:creator>Regina Hoo</dc:creator>
<dc:creator>Peng He</dc:creator>
<dc:creator>Kerstin B Meyer</dc:creator>
<dc:creator>Sarah A Teichmann</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Automatic cell-type harmonization and integration across Human Cell Atlas datasets</dc:title>
<dc:identifier>pmid:38134877</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.026</dc:identifier>
</item>
<item>
<title>Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134876/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>Short tandem repeat (STR) instability causes transcriptional silencing in several repeat expansion disorders. In fragile X syndrome (FXS), mutation-length expansion of a CGG STR represses FMR1 via local DNA methylation. Here, we find megabase-scale H3K9me3 domains on autosomes and encompassing FMR1 on the X chromosome in FXS patient-derived iPSCs, iPSC-derived neural progenitors, EBV-transformed lymphoblasts, and brain tissue with mutation-length CGG expansion. H3K9me3 domains connect via...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5840-5858.e36. doi: 10.1016/j.cell.2023.11.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Short tandem repeat (STR) instability causes transcriptional silencing in several repeat expansion disorders. In fragile X syndrome (FXS), mutation-length expansion of a CGG STR represses FMR1 via local DNA methylation. Here, we find megabase-scale H3K9me3 domains on autosomes and encompassing FMR1 on the X chromosome in FXS patient-derived iPSCs, iPSC-derived neural progenitors, EBV-transformed lymphoblasts, and brain tissue with mutation-length CGG expansion. H3K9me3 domains connect via inter-chromosomal interactions and demarcate severe misfolding of TADs and loops. They harbor long synaptic genes replicating at the end of S phase, replication-stress-induced double-strand breaks, and STRs prone to stepwise somatic instability. CRISPR engineering of the mutation-length CGG to premutation length reverses H3K9me3 on the X chromosome and multiple autosomes, refolds TADs, and restores gene expression. H3K9me3 domains can also arise in normal-length iPSCs created with perturbations linked to genome instability, suggesting their relevance beyond FXS. Our results reveal Mb-scale heterochromatinization and trans interactions among loci susceptible to instability.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134876/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38134876</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.019>10.1016/j.cell.2023.11.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134876</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Thomas Malachowski</dc:creator>
<dc:creator>Keerthivasan Raanin Chandradoss</dc:creator>
<dc:creator>Ravi Boya</dc:creator>
<dc:creator>Linda Zhou</dc:creator>
<dc:creator>Ashley L Cook</dc:creator>
<dc:creator>Chuanbin Su</dc:creator>
<dc:creator>Kenneth Pham</dc:creator>
<dc:creator>Spencer A Haws</dc:creator>
<dc:creator>Ji Hun Kim</dc:creator>
<dc:creator>Han-Seul Ryu</dc:creator>
<dc:creator>Chunmin Ge</dc:creator>
<dc:creator>Jennifer M Luppino</dc:creator>
<dc:creator>Son C Nguyen</dc:creator>
<dc:creator>Katelyn R Titus</dc:creator>
<dc:creator>Wanfeng Gong</dc:creator>
<dc:creator>Owen Wallace</dc:creator>
<dc:creator>Eric F Joyce</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:creator>Luis Alejandro Rojas</dc:creator>
<dc:creator>Jennifer E Phillips-Cremins</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome</dc:title>
<dc:identifier>pmid:38134876</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.019</dc:identifier>
</item>
<item>
<title>Structural evolution of fibril polymorphs during amyloid assembly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134875/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231228150809&amp;v=2.18.0
      <description>Cryoelectron microscopy (cryo-EM) has provided unprecedented insights into amyloid fibril structures, including those associated with disease. However, these structures represent the endpoints of long assembly processes, and their relationship to fibrils formed early in assembly is unknown. Consequently, whether different fibril architectures, with potentially different pathological properties, form during assembly remains unknown. Here, we used cryo-EM to determine structures of amyloid fibrils...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5798-5811.e26. doi: 10.1016/j.cell.2023.11.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cryoelectron microscopy (cryo-EM) has provided unprecedented insights into amyloid fibril structures, including those associated with disease. However, these structures represent the endpoints of long assembly processes, and their relationship to fibrils formed early in assembly is unknown. Consequently, whether different fibril architectures, with potentially different pathological properties, form during assembly remains unknown. Here, we used cryo-EM to determine structures of amyloid fibrils at different times during in vitro fibrillation of a disease-related variant of human islet amyloid polypeptide (IAPP-S20G). Strikingly, the fibrils formed in the lag, growth, and plateau phases have different structures, with new forms appearing and others disappearing as fibrillation proceeds. A time course with wild-type hIAPP also shows fibrils changing with time, suggesting that this is a general property of IAPP amyloid assembly. The observation of transiently populated fibril structures has implications for understanding amyloid assembly mechanisms with potential new insights into amyloid progression in disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134875/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231228150809&v=2.18.0">38134875</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.025>10.1016/j.cell.2023.11.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134875</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Martin Wilkinson</dc:creator>
<dc:creator>Yong Xu</dc:creator>
<dc:creator>Dev Thacker</dc:creator>
<dc:creator>Alexander I P Taylor</dc:creator>
<dc:creator>Declan G Fisher</dc:creator>
<dc:creator>Rodrigo U Gallardo</dc:creator>
<dc:creator>Sheena E Radford</dc:creator>
<dc:creator>Neil A Ranson</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural evolution of fibril polymorphs during amyloid assembly</dc:title>
<dc:identifier>pmid:38134875</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.025</dc:identifier>
</item>





























</channel>
</rss>